You are here: Industry Insights > oesophageal cancer

News List

Opdivo combos show OS benefit in advanced oesophageal cancer pharmatimes
June 10, 2021
Bristol Myers Squibb’s (BMS) immunotherapy Opdivo, when administered alongside chemotherapy or Yervoy, demonstrated significant overall survival (OS) benefit compared to chemotherapy alone in advanced/metastatic oesophageal cancer patients.
Tislelizumab reduces risk of death by 30 percent in oesophageal cancer trial europeanpharmaceuticalreview
June 08, 2021
In a Phase III trial, Novartis’ investigational checkpoint inhibitor tislelizumab improved overall survival in patients with oesophageal squamous cell carcinoma.
EMA launches review of BMS’ Opdivo for oesophageal cancer pharmatimes
January 06, 2021
The European Medicines Agency (EMA) has launched its centralized review process for Bristol Myers Squibb’s Opdivo (nivolumab) as an adjuvant treatment for oesophageal or gastroesophageal junction (GEJ) cancer.
BMS’ Opdivo improves survival in gastric and oesophageal cancers pharmatimes
August 13, 2020
Bristol Myers Squibb has revealed the results from the Phase III CheckMate-649 evaluating Opdivo (nivolumab) plus chemotherapy in first-line metastatic gastric cancer, gastroesophageal junction (GEJ) cancer or oesophageal adenocarcinoma.
MSD’s Keytruda shows benefit in oesophageal cancer trial pharmatimes
November 19, 2018
MSD’s Keytruda has shown promise in a late-stage trial testing its safety and efficacy in patients with advanced or metastatic esophageal or esophagogastric junction carcinoma.
Scientists identify bacterial link with oesophageal cancer europeanpharmaceuticalreview
December 04, 2017
Researchers at NYU Langone Health’s Perlmutter Cancer Center report that at least three kinds of bacteria in the mouths of Americans may directly affect their risk of developing oesophageal cancer.
New test could detect oesophageal cancer years earlier pharmatimes
November 08, 2017
Scientists have developed a new genetic test that they believe could help diagnose oesophageal cancer up to eight years before symptoms appear in people at a high risk of the disease.
Scientists discover ‘Achilles’ heel’ of oesophageal cancer pharmafile
August 24, 2017
Researchers from The Institute of Cancer Research have potentially found a new use for Imbruvica, after discovering a weakness in certain types of oesophageal cancer.